Exclusion Criteria

1. Previous use of systemic therapy targeting CSF1 or CSF1R; previous therapy with imatinib and nilotinib is allowed
2. Treatment for TGCT, including investigational therapy, within 14 days prior to administration of study drug. For immediate prior therapies with a half-life longer than 3 days, or if the halflife is not available, the interval must be ≥28 days prior to the first administration of study drug
3. Known metastatic TGCT or other active cancer that requires concurrent treatment (exceptions will be considered on a case-by-case basis depending on tumor type, stage, location, planned treatment, and expected recovery after discussion and approval by Sponsor)
4. Baseline prolongation of the QTcF based on repeated demonstration of QTcF >450 ms in males or >470 ms in females or history of long QT syndrome
5. Receive concurrent treatment with any prohibited medications
6. Major surgery within 14 days of the first dose of study drug; following major surgeries >14 days prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence
7. Any clinically significant comorbidities, such as significant concomitant arthropathy in the affected joint, or any other serious medical or psychiatric condition(s), known current alcohol abuse, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the participant to safety risks
8. Active liver or biliary disease including evidence of fatty liver, nonalcoholic steatohepatitis (NASH), or cirrhosis
9. Malabsorption syndrome or other illness that could affect oral absorption as judged by the Investigator
10. Known active human immunodeficiency virus (HIV), active or chronic hepatitis B, active or chronic hepatitis C, or known active mycobacterium tuberculosis infection
11. If female, the participant is pregnant or lactating
12. Known allergy or hypersensitivity to any component of the study drug
13. Contraindication to MRI